Insider Sale Details
Alfred J. Ford Jr., Chief Commercial Officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), disposed of a total of 27,632 common shares for approximately $642,523. The transactions occurred on July 30 (5,936 shares), July 31 (8,681 shares) and August 3, 2026 (13,015 shares) at per‑share prices ranging from $22.6108 to $23.9046. The filings describe the sales as nondiscretionary, undertaken to satisfy tax‑withholding obligations arising from the vesting and settlement of restricted stock units.
Post‑Sale Holding and Stock Performance
Following the sales, Mr. Ford’s direct holding in Kestra Medical Technologies stands at 105,839 common shares. Over the preceding twelve months the company’s share price has appreciated roughly 75%, currently trading around $28.02, which is near its 52‑week high of $30. InvestingPro’s analysis flags the stock as overvalued relative to its fair‑value estimate, placing it on a “Most Overvalued” list. Kestra’s market capitalization is cited at $1.63 billion, and the firm remains unprofitable, reporting negative earnings of $2.43 per share over the last twelve months.
Quarterly Financial Results
In its fiscal fourth quarter of 2026, Kestra Medical Technologies posted revenue of $28.64 million, a 66% year‑over‑year increase that exceeded the consensus estimate of $26.5 million. Despite the top‑line growth, the company recorded an adjusted loss of $0.67 per share, wider than the consensus expectation of a $0.58 loss.
Analyst Coverage and Outlook
Stifel reiterated a Buy rating with a price target of $30, citing strong revenue growth and record prescriptions for the ASSURE wearable cardioverter‑defibrillator. Wolfe Research raised its target to $30 from $29, emphasizing the company’s execution strength. JPMorgan initiated coverage with an Overweight rating, highlighting the potential of the ASSURE WCD in a market historically dominated by a single incumbent. Oppenheimer assigned a Perform rating, noting a large addressable market and increasing market share against competitor ZOLL.
This article was generated with AI assistance and reviewed by an editor.